Comparison
Setmelanotide vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
920014-72-8
2179963-22-7
Molecular weight
1117.32 g/mol
4727 g/mol
Half-life
11 h
168 h
Sequence
Ac-Arg-Cys(1)-D-Ala-His-D-Phe-Arg-Trp-Cys(1)-NH2 (zyklisches Oktapeptid, Disulfidbrücke Cys2–Cys8)modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Setmelanotide
Setmelanotide is an agonist at the melanocortin-4 receptor (MC4R), a central receptor of the hypothalamic melanocortin pathway involved in the control of energy balance, satiety and body weight. In certain genetic defects (e.g. in POMC, PCSK1 or LEPR), the natural activation of MC4R is reduced. Setmelanotide activates MC4R directly, thereby bypassing the upstream defect. This description is mechanistic and neutral and does not constitute a recommendation for use.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
4
of which in humans
3
4
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
3
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Setmelanotide and Survodutide?
- Setmelanotide is classified as "Metabolic", while Survodutide is classified as "Metabolic". Setmelanotide: Setmelanotide (brand name Imcivree) is a synthetic cyclic octapeptide and an agonist at the melanocortin-4 receptor (MC4R). It was developed and approved as a prescription medicine for chronic weight management in rare genetic forms of obesity within the MC4R signalling pathway (including POMC, PCSK1 and LEPR deficiency as well as Bardet-Biedl syndrome). The following information is provided for informational and educational purposes only. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Setmelanotide or Survodutide?
- The highest available evidence level is "Human RCT" for Setmelanotide and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Setmelanotide and Survodutide in Germany and the United States?
- Germany: Setmelanotide — Prescription, Survodutide — Unapproved. United States: Setmelanotide — Prescription, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.